#### Edgar Filing: ACURA PHARMACEUTICALS, INC - Form 4

ACURA PH Form 4 May 27, 200	IARMACEUTIC	ALS, INC	l								
FORM									OMB A	PPROVAL	
	UNITED	STATES		RITIES A			NGE (	COMMISSIO	N OMB Number:	3235-0287	
if no lon subject t Section Form 4 e Form 5 obligatio may con	obligations may continue. See InstructionSection 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940							Estimated burden hoi response	Estimated average burden hours per response 0.5		
(Print or Type	Responses)										
1. Name and Address of Reporting Person <u>*</u> Jones Robert B			2. Issuer Name <b>and</b> Ticker or Trading Symbol ACURA PHARMACEUTICALS, INC [ACUR]				-	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) C/O ACUR PHARMAO N NORTH	A CEUTICALS, INC	Middle) C., 616		of Earliest Tr Day/Year) 2008	ransaction			Director X Officer (gi below)		% Owner her (specify	
			4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State)	(Zip)	Tab	le I - Non-I	Derivative	Securit	ties Ac	quired, Disposed	of. or Beneficia	llv Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution Date, if TransactionAcqu any Code Dispo		4. Securit nAcquired Disposed (Instr. 3, 4	ies (A) or of (D) 4 and 5) (A) or		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		7. Nature of Indirect		
Reminder: Re	port on a separate line	e for each cl	ass of sec	urities benef	ficially ow	ned dire	ctly or	indirectly.			

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Expiration Date		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	\$ 9.87 <u>(1)</u>	05/23/2008		А	160,000	(2)	05/23/2018	Common Stock	160,000

#### Edgar Filing: ACURA PHARMACEUTICALS, INC - Form 4

## **Reporting Owners**

Reporting Owner Name / Address	Relationships					
The bound of the state of the second	Director	10% Owner	Officer	Other		
Jones Robert B C/O ACURA PHARMACEUTICALS, INC. 616 N NORTH COURT PALATINE, IL 60067			Sr. VP & COO			
Signatures						

## Signatures

/s/ Robert B. Jones

**<u>\*\*</u>**Signature of Reporting Person 05/27/2008

Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents closing price of Issuer's common stock on the Nasdaq Capital Market on 5/22/2008.
- Option vests and becomes exercisable in 24 equal monthly installments from June 23, 2008 through May 23, 2010, unless certain events (2)cause vesting and exercisability to be accelerated.
- (3) Not Applicable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.